» Authors » Ai Yamada

Ai Yamada

Explore the profile of Ai Yamada including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 183
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagasawa S, Nishimura T, Yamada A, Kamimura S, Ishimura M, Moritake H
Hum Genome Var . 2024 Nov; 11(1):41. PMID: 39572557
We describe a case of RAS-associated autoimmune leukoproliferative disease with primary ciliary dyskinesia (PCD)-like symptoms, such as recurrent pneumonia, sinusitis, and otitis media, that occurred 7 years after hematopoietic cell...
2.
Ishii K, Takeuchi A, Shimada M, Momokawa H, Tashiro T, Yamada A, et al.
J Occup Health . 2024 Oct; 66(1). PMID: 39364697
Objective: We aimed to develop a reliable gas chromatography-mass spectrometry (GC-MS) method for detecting urinary benzyl alcohol (BeOH) concentrations and assess the suitability of urinary BeOH as a biomarker for...
3.
Kinoshita M, Saito Y, Otani K, Uehara Y, Nagasawa S, Nakagawa M, et al.
Int J Hematol . 2024 Sep; 120(5):601-612. PMID: 39283580
Acute myeloid leukemia (AML) cells are highly dependent on oxidative phosphorylation and the mitochondrial dynamics regulated by fusion-related genes MFN1, MFN2, and OPA1 and fission-related genes DNM1L and MFF. An...
4.
Kato S, Nakashima K, Yamato G, Saito S, Taneyama Y, Yamamoto N, et al.
Pediatr Blood Cancer . 2024 Aug; 71(10):e31244. PMID: 39099137
Hypomethylating agent treatment for myeloid leukemia associated with Down syndrome (ML-DS) has been scarcely reported. Herein, we collected information on azacitidine treatment for ML-DS in Japan. Forty-eight cycles of azacitidine...
5.
Matsumoto F, Yokogami K, Yamada A, Moritake H, Watanabe T, Yamashita S, et al.
Hum Cell . 2024 Feb; 37(2):523-530. PMID: 38329694
Atypical teratoid/rhabdoid (AT/RT) is a rare and highly malignant tumor of the central nervous system (CNS). It is most commonly found in children less than 5 years of age and...
6.
Nagasawa S, Yamada A, Nakagawa M, Kinoshita M, Koga Y, Ohga S, et al.
Pediatr Blood Cancer . 2023 Dec; 71(2):e30802. PMID: 38053231
No abstract available.
7.
Harada M, Yamada A, Nagasawa S, Yamashita N, Kinoshita M, Yoshiura K, et al.
Pediatr Int . 2023 Oct; 65(1):e15652. PMID: 37804043
No abstract available.
8.
Kubota I, Nagasawa S, Nakagawa M, Yamada A, Kinoshita M, Kamimura S, et al.
Rinsho Ketsueki . 2023 Sep; 64(8):741-745. PMID: 37673625
Immunosuppressive therapy (IST) is the first-line treatment for patients with aplastic anemia (AA) who require blood transfusion when a human leukocyte antigen-matched related donor is unavailable. However, the proportion of...
9.
Otomi K, Yamada A, Kurogi J, Kamimura S, Moritake H
Pediatr Int . 2023 Aug; 65(1):e15593. PMID: 37615371
No abstract available.
10.
Yamada A, Kinoshita M, Kamimura S, Jinnouchi T, Azuma M, Yamashita S, et al.
Pediatr Hematol Oncol . 2023 Jul; 40(7):629-642. PMID: 37519026
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare aggressive central nervous system tumor that typically affects children under three years old and has poor survival with a high risk for neurologic...